On August 2 2023, KARYOPHARM THERAPEUTICS ($NASDAQ:KPTI) released their earnings results for the second quarter of FY2023 (ending June 30 2023). Total revenue for the quarter totaled USD 37.6 million, a 5.3% dip from the same period in the previous year. Net income came out to -32.6 million, which was a marked improvement compared to the -49.1 million posted in the prior year.
The stock opened at $1.9 and closed at $1.8, reflecting a decrease of 0.6% from its last closing price of $1.8. The earnings report highlighted the company’s progress in developing novel treatments in the areas of oncology and hematology. Last quarter, KARYOPHARM THERAPEUTICS focused on advancing their pipeline of oncology and hematology therapeutics, while also building a strong foundation for long-term growth. KARYOPHARM THERAPEUTICS has achieved promising results in the development and launch of its therapeutic agents including Selinexor (Xpovio), which is approved in more than 30 countries for the treatment of certain types of refractory multiple myeloma, and Xpovio-based combination regimens that are being studied in Phase 3 clinical trials in a variety of settings.
In addition to their research and development efforts, KARYOPHARM THERAPEUTICS has also been making strategic acquisitions and collaborations that will help them expand their presence in the global healthcare market. Although the stock price has dropped by 0.6% from last closing price, investors remain optimistic that KARYOPHARM THERAPEUTICS will continue to deliver strong performance throughout the rest of the fiscal year. With their pipeline of promising new treatments and strategic partnerships, KARYOPHARM THERAPEUTICS is well-positioned to capitalize on the evolving treatments landscape and remain a leader in oncology and hematology therapeutics industry. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Karyopharm Therapeutics. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Karyopharm Therapeutics. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Karyopharm Therapeutics. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Karyopharm Therapeutics are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Karyopharm Therapeutics Stock Fair Value Calculation
GoodWhale recently conducted an analysis of KARYOPHARM THERAPEUTICS‘ wellbeing and determined the fair value of their shares to be around $5.7. We used our proprietary Valuation Line to reach this conclusion. Currently, KARYOPHARM THERAPEUTICS stock is being traded at $1.8, which is undervalued by a significant 68.5%. This indicates that this is a great time to buy and invest in the company’s shares. We believe that investing in KARYOPHARM THERAPEUTICS is a promising opportunity for anyone looking to benefit from the company’s growth in the future. More…
Risk Rating Analysis
Star Chart Analysis
The competition among Karyopharm Therapeutics Inc, Soleno Therapeutics Inc, Neovacs SA, and Shanghai Allist Pharmaceuticals Co Ltd is fierce. All four companies are vying for a share of the market for new cancer treatments. Karyopharm Therapeutics Inc has the most experience in developing new cancer treatments, but its competitors are quickly catching up. Soleno Therapeutics Inc has the most experience in clinical trials, but Neovacs SA has the most experience in manufacturing. Shanghai Allist Pharmaceuticals Co Ltd is the only company with experience in both developing new cancer treatments and manufacturing.
– Soleno Therapeutics Inc ($NASDAQ:SLNO)
Soleno Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare cardiovascular and metabolic diseases. The company’s lead product candidate is diazoxide choline controlled-release (DCCR), a once-daily oral tablet for the treatment of primary pulmonary hypertension (PPH) and other rare cardiovascular diseases. Soleno has completed a Phase 2 clinical trial of DCCR in patients with PPH and is currently enrolling patients in a Phase 3 clinical trial. The company also has a portfolio of other product candidates in various stages of development for the treatment of diabetes and other metabolic diseases.
Headquartered in Paris, France, Neovacs is a biopharmaceutical company focused on the development of active immunotherapies for the treatment of autoimmune and inflammatory diseases. The company’s lead product candidates are IFNalpha-Kinoid and TNF-Kinoid, which are in clinical development for the treatment of systemic lupus erythematosus and rheumatoid arthritis, respectively.
– Shanghai Allist Pharmaceuticals Co Ltd ($SHSE:688578)
Shanghai Allist Pharmaceuticals Co Ltd is a pharmaceutical company that manufactures and sells drugs in China. The company has a market cap of 10.29B as of 2022 and a Return on Equity of 2.58%. Allist is a leading manufacturer of drugs in China and has a strong presence in the domestic market. The company’s products are used in the treatment of various diseases and disorders, including cancer, cardiovascular disease, and diabetes. Allist has a strong research and development capability and has a number of new drugs in its pipeline. The company is well-positioned to benefit from the growing demand for pharmaceutical products in China.
Karyopharm Therapeutics has released its second quarter earnings results for 2023. Total revenue for Q2 was USD 37.6 million, a 5.3% decrease year-over-year. Net income was -32.6 million, showing a strong improvement from the -49.1 million posted in the same period of the prior year.
Investors may find this encouraging, as it demonstrates the company’s ability to manage expenses and maintain profitability despite lower revenue. Karyopharm’s continued commitment to fiscal responsibility and strong financial performance suggests it may be an attractive investment option in the near future.